MAP2K7 and melanoma: METRIC (MEK Versus Dacarbazine [DTIC] or Paclitaxel [Taxol] in Metastatic Melanoma) was a randomized, multicenter phase 3 trial evaluating the efficacy and safety of trametinib compared with standard chemotherapy (dacarbazine or paclitaxel) in patients with advanced or metastatic (stage IIIc or IV) BRAF V600E/K mutation–positive melanoma.